Group 1 - Chengjian Development received a dividend of 7.1282 million yuan from Beijing Jingcheng Jiaye Property Co., Ltd., in which it holds a 33.47% stake [1] - Shengnuo Bio expects a net profit attributable to shareholders of 77.0275 million to 94.1448 million yuan for the first half of 2025, representing a year-on-year increase of 253.54% to 332.10% [1] - JKN2301 dry mixed suspension has been approved for clinical trials, targeting children with influenza [5][6] Group 2 - Jindawei obtained a patent for a method of purifying natto kinase, with a validity of twenty years [2] - CITIC Guoan plans to increase its stake in China Broadcasting Hunan Company to approximately 5.29% through a capital increase of 278 million yuan [2] - Ji Electric announced the resignation of its general manager, Niu Guojun, due to work changes [3] Group 3 - Xintian Green Energy successfully issued 1.5 billion yuan in green medium-term notes with a term of 3+N years and an interest rate of 2.05% [7] - Hengrun Co. plans to invest 1.2 billion yuan in a project to produce 2,000 sets of wind turbine gearbox components [9] - Pulaide received a government subsidy of 10 million yuan, accounting for 15.87% of its audited net profit for the last fiscal year [10] Group 4 - Boteng Co. passed the EU QP audit, receiving a compliance statement for its CDMO services [12] - Zhou Dasheng added 7 self-operated stores in May, with total investments ranging from 900,000 to 6.5 million yuan [13] - Wantai Bio initiated a Phase III clinical trial for its live attenuated varicella vaccine [15] Group 5 - Shanghai Pharmaceuticals received a drug registration certificate for Pregabalin capsules in Thailand [19] - Sanxing Medical's subsidiary is expected to win contracts worth approximately 143 million yuan from State Grid projects [21] - Jiangsu Huachen plans to issue 460 million yuan in convertible bonds [24] Group 6 - Jian Gong Repair won a soil pollution remediation project worth 32.76 million yuan [25] - Dize Pharmaceutical completed patient enrollment for a global Phase III clinical trial of its drug [26] - Del Co. received acceptance for its application to issue shares for asset acquisition and raise matching funds [27] Group 7 - Beijing Kerui won multiple power grid projects with a total value of approximately 154 million yuan [27] - Xie Chuang Data signed financing lease contracts totaling 498 million yuan with Su Yin Financial Leasing [28] - Meige Intelligent submitted an application for H-share listing on the Hong Kong Stock Exchange [29][31] Group 8 - Aikodi plans to repurchase shares worth 100 million to 200 million yuan for employee stock ownership plans [54] - Kong Kong Industrial intends to sell 80% of Tianyuan Construction to its controlling shareholder [55] - Youyou Green Energy proposed a cash dividend of 12 yuan per 10 shares, totaling 50.4 million yuan [55]

Core Viewpoint - Chengdu Sanno Biological Technology Co., Ltd. expects significant growth in net profit for the first half of 2025, driven by market expansion and increased sales efforts in the peptide industry [1][2]. Financial Performance Forecast - The company anticipates a net profit attributable to shareholders of the parent company between 77.03 million yuan and 102.36 million yuan, representing an increase of 253.54% to 332.10% compared to the previous year [1]. - The expected net profit after deducting non-recurring gains and losses is projected to be between 77.35 million yuan and 94.53 million yuan, reflecting a year-on-year increase of 304.49% to 394.38% [1][2]. - For reference, the net profit for the same period last year was 21.79 million yuan, with a net profit of 19.12 million yuan after deducting non-recurring gains and losses [1]. Reasons for Performance Change - The company is closely following the development trends in the peptide industry and is actively expanding its marketing efforts both domestically and internationally, which has significantly boosted net profit [2].

[Announcement Statement](index=1&type=section&id=Announcement%20Statement) Chengdu Senor Bio-Technology Co., Ltd. announces its 2025 semi-annual performance forecast, board guarantees content accuracy - Chengdu Senor Bio-Technology Co., Ltd. issues a voluntary disclosure announcement for its 2025 semi-annual performance forecast, with the board guaranteeing the truthfulness, accuracy, and completeness of the content[1](index=1&type=chunk) [2025 Semi-Annual Performance Forecast Overview](index=1&type=section&id=Item%20I.%20Current%20Period%20Performance%20Forecast) The company forecasts significant year-over-year growth in H1 2025 net profit and non-recurring net profit [Forecast Period](index=1&type=section&id=%28I%29%20Performance%20Forecast%20Period) This performance forecast covers the financial period from January 1, 2025, to June 30, 2025 - The performance forecast period is from January 1, 2025, to June 30, 2025[2](index=2&type=chunk) [Key Financial Indicator Forecast](index=1&type=section&id=%28II%29%20Performance%20Forecast%20Details) The company forecasts substantial year-over-year growth in H1 2025 net profit and non-recurring net profit Key Performance Forecast Indicators for H1 2025 | Indicator | Estimated Amount (10,000 CNY) | Year-over-Year Increase (10,000 CNY) | Year-over-Year Growth (%) | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Parent | 7,702.75 to 9,414.48 | 5,523.99 to 7,235.71 | 253.54 to 332.10 | | Net Profit After Non-Recurring Items | 7,734.64 to 9,453.45 | 5,822.44 to 7,541.25 | 304.49 to 394.38 | [Audit Status](index=1&type=section&id=%28III%29%20This%20Performance%20Forecast%20is%20Unaudited) This performance forecast is a preliminary, unaudited calculation by the finance department - This performance forecast is unaudited by a certified public accountant and represents preliminary calculations by the finance department[4](index=4&type=chunk) [Review of Prior Year's Performance](index=1&type=section&id=Item%20II.%20Prior%20Year%20Performance) This section reviews the company's H1 2024 financial performance, providing a baseline for the current forecast Key Financial Data for H1 2024 | Indicator | Amount (10,000 CNY) | | :--- | :--- | | Net Profit Attributable to Parent | 2,178.76 | | Net Profit After Non-Recurring Items | 1,912.20 | | Total Profit | 2,329.99 | | Earnings Per Share (CNY/share) | 0.19 | [Main Reasons for Performance Change](index=1&type=section&id=Item%20III.%20Main%20Reasons%20for%20Current%20Period%20Performance%20Change) Performance growth is driven by peptide industry trends, expanded marketing, and strong peptide API sales - The company closely followed peptide industry development trends, continuously expanded domestic and international marketing, and intensified product sales efforts[6](index=6&type=chunk) - In the first half of 2025, the company's peptide API business performed well, driving a significant year-over-year increase in net profit[6](index=6&type=chunk) [Risk Warning](index=1&type=section&id=Item%20IV.%20Risk%20Warning) Investors are cautioned about unaudited preliminary data and revenue recognition uncertainties [Unaudited Performance Forecast](index=2&type=section&id=1.%20Unaudited%20Performance%20Forecast) This performance forecast is a preliminary, unaudited calculation, subject to potential adjustments - This performance forecast represents preliminary calculations by the finance department and has not been audited by a certified public accountant[8](index=8&type=chunk) [Revenue Recognition Uncertainty](index=2&type=section&id=2.%20Revenue%20Recognition%20Uncertainty) Certain orders face revenue recognition uncertainty within the reporting period due to factors like shipment and logistics - Revenue recognition for some orders within the reporting period is uncertain due to factors such as shipment and logistics[8](index=8&type=chunk) [Other Matters](index=2&type=section&id=Item%20V.%20Other%20Matters) The company reminds investors that forecast data is preliminary; final figures will be in the 2025 semi-annual report, caution advised - The forecast data is preliminary, and final financial figures will be based on the 2025 semi-annual report[9](index=9&type=chunk) - Investors are advised to exercise caution regarding investment risks[9](index=9&type=chunk)

Core Viewpoint - The company expects significant growth in net profit for the first half of 2025, with projections indicating an increase of over 250% compared to the same period last year [1] Financial Projections - The company anticipates a net profit attributable to shareholders ranging from 77.03 million to 94.14 million yuan for the first half of 2025, representing an increase of 55.24 million to 72.36 million yuan year-on-year, which corresponds to a growth rate of 253.54% to 332.10% [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between 77.35 million and 94.53 million yuan, with an increase of 58.22 million to 75.41 million yuan compared to the previous year, reflecting a growth rate of 304.49% to 394.38% [1]

Group 1 - Kaichun Co., Ltd. adjusted the share repurchase price limit from 26.625 yuan/share to 40 yuan/share, effective from June 10, 2025 [1] - Yipin Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, a Class 3 chemical drug used for sedation during anesthesia [1] - Bohui Innovation obtained a medical device registration certificate for HPV Genotyping Test Kit, used for qualitative detection of HPV DNA [1][2] Group 2 - Lingyi Zhi Zao's application for issuing convertible bonds and cash payment to acquire 66.46% of Jiangsu Kedasiteng Automotive Technology Co., Ltd. has been accepted by the Shenzhen Stock Exchange [3] - Kemin Food reported a 23.06% year-on-year increase in pig sales in May, with a total of 48,300 pigs sold [4][5] - Meian Sen decided to terminate the issuance of shares to specific objects due to market conditions and strategic considerations [6][7] Group 3 - Zhengbang Technology reported a 146.6% year-on-year increase in pig sales revenue in May, totaling 731 million yuan [9] - Yuanda Holdings plans to reduce the registered capital of its subsidiary from 73 million to 24.3 million USD to optimize asset structure [10] - East China Pharmaceutical's subsidiary received FDA approval for clinical trials of HDM1010 tablets for type 2 diabetes [12] Group 4 - Liangxin Co., Ltd. received a government subsidy of 14.1 million yuan, accounting for 4.52% of its audited net profit for 2024 [13] - Erkang Pharmaceutical's Vitamin B6 Injection passed the consistency evaluation for generic drugs [14] - New Industry received a patent certificate for an antibody related to anti-PIC detection, enhancing detection efficiency [16][15] Group 5 - Dongxing Medical signed a 6 million yuan technology development contract with Shanghai Jiao Tong University for collagen preparation processes [16] - Suchang Chai A's subsidiary will absorb and merge another subsidiary, adjusting internal equity structure [17] - Yibin Technology received a project designation notice from a domestic new energy vehicle company, with an estimated total sales of 256 million yuan over five years [18] Group 6 - Mingchen Health received a cash dividend of 20 million yuan from its subsidiary [19] - Hendi Pharmaceutical obtained a drug registration certificate for Ibuprofen Suspension, a common medication for children [19] - Huaren Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, classified as a Category B drug under national medical insurance [20] Group 7 - Enwei Pharmaceutical obtained a renewed drug production license for six key products [21] - Xiaoming Co., Ltd. reported a 45.59% year-on-year increase in chicken product sales in May, totaling 23.25 million birds [23][24] - Shan Natural Gas successfully issued a 350 million yuan short-term financing bond with a 1.78% interest rate [25] Group 8 - Xidamen announced plans for board members to reduce their holdings by up to 581,000 shares [26] - Shentong Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [27] - Saintno Bio plans to distribute a cash dividend of 0.14 yuan per share and a capital increase of 0.4 shares per share [28] Group 9 - *ST King Kong's subsidiary received a debt transfer notice from its controlling shareholder, totaling 364 million yuan [29] - Foxit Software's executives plan to reduce their holdings by a total of 55,800 shares [30] - Youyou Green Energy plans to apply for a bank credit line of up to 1.5 billion yuan [31] Group 10 - Guoxing Optoelectronics plans to distribute a cash dividend of 0.5 yuan per 10 shares [32] - Guangxun Technology plans to distribute a cash dividend of 2.6 yuan per 10 shares [33] - Hanrui Cobalt plans to distribute a cash dividend of 1.5 yuan per 10 shares [35] Group 11 - Tigermed plans to distribute a cash dividend of 3 yuan per 10 shares [37] - Shenliang Holdings plans to distribute a cash dividend of 1.5 yuan per 10 shares [38] - Yishitong plans to distribute a cash dividend of 1 yuan per 10 shares [39]

A股创新药板块持续走强，盘中掀起涨停潮，睿智医药、众生药业、罗欣药业、联化科技等多股封板涨 停，常山药业、泰恩康涨超10%，一品红、悦康药业、圣诺生物等跟涨。 ...

本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股现金红利0.14元 每股转增0.4股 本次利润分配及转增股本方案经公司2025年5月15日的2024年年度股东会审议通过。 二、分配、转增股本方案 1.发放年度：2024年年度 2.分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分公司（以下简 称"中国结算上海分公司"）登记在册的本公司全体股东。 3.分配方案： 本次利润分配及转增股本以方案实施前的公司总股本112,418,556股为基数，每股派发现金红利0.14元 （含税），以资本公积金向全体股东每股转增0.4股，共计派发现金红利15,738,597.84元，转增 44,967,422股，本次分配后总股本为157,385,978股。 三、相关日期 ■ 四、分配、转增股本实施办法 1.实施办法 （1）公司全部股东（包括无限售条件流通股及有限售条件流通股）的红利均委托中国结算上海分公 司，通过其资金清算系统向股权登记日上海证券交易所收市后登记在册并在上海证券交易所各会员办 ...

证券代码：688117 证券简称：圣诺生物 公告编号：2025-018 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 新增无限售条件流 | 现金红利发放日 | | --- | --- | --- | --- | | | | 通股份上市日 | | | 2025/6/12 | 2025/6/13 | 2025/6/13 | 2025/6/13 | 一、 通过分配、转增股本方案的股东会届次和日期 本次利润分配及转增股本方案经公司2025 年 5 月 15 日的2024年年度股东会审 议通过。 二、 分配、转增股本方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司存在首发战略配售股份，首发战略配售股份已全部上市流通 是否涉及差异化分红送转：否 每股分配比例，每股转增比例 每股现金红利0.14元 每股转增0.4股 相关日期 1. 发放年度：2024年年度 2. 分派对象： 成都圣诺生物科技股份有限公司 2024年年度权益分派实施公告 （2）公司本次资本 ...

Group 1 - The company, Chengdu Sanofi Biotech Co., Ltd., will hold a performance briefing for the fiscal year 2024 and the first quarter of 2025 on May 26, 2025, from 10:00 to 11:00 AM [2][3][4] - The briefing will be conducted in an interactive text format via the Shanghai Stock Exchange Roadshow Center, allowing investors to ask questions [2][5] - Investors can submit questions from May 19 to May 23, 2025, before 4:00 PM, through the Roadshow Center's website or via the company's email [2][5][6] Group 2 - The company held its annual general meeting on May 15, 2025, at its headquarters in Chengdu, Sichuan Province [9][10] - All board members and supervisors attended the meeting, ensuring compliance with legal and regulatory requirements [11][17] - Various resolutions were passed, including the approval of the 2024 annual report, financial budget for 2025, and the proposal for the distribution of profits [12][13][15]

证券代码：688117 证券简称：圣诺生物 公告编号：2025-016 成都圣诺生物科技股份有限公司 关于召开 2024 年度暨 2025 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （网址:https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络文字互动 投资者可于 2025 年 5 月 19 日（星期一）至 2025 年 5 月 23 日（星期五） 下午 16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮 箱(snkj@snbiopharm.com)进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 成都圣诺生物科技股份有限公司（以下简称"公司"）已于 2025 年 4 月 25 日在上海证券交易所网站（www.sse.com.cn）披露公司《2024 年年度报告》《2025 年第一季度报告》，为便于广大投资者更全面深入地了解公司 2024 年年度、2025 年第一季度经营成果、财务状况，公司计划于 20 ...